On October 9, 2023 TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, reported to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at 2023 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, and in breast cancer at 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting respectively (Press release, TransThera Biosciences, OCT 9, 2023, View Source [SID1234635725]). TransThera will also give a poster presentation of tinengotinib phase 1b/2 clinical data in Chinese patients at 2023 ESMO (Free ESMO Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2023 ESMO (Free ESMO Whitepaper), October 22-24, Madrid, Spain

Mini-Oral Presentation, Abstract #95MO
Title: Tinengotinib in Patients with Advanced, Fibroblast Growth Factor Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma
Presenter: Meredith S Pelster, MD

Poster presentation, Abstract #670P
Title: Preliminary Efficacy and Safety of Tinengotinib (TT-00420) Monotherapy in Chinese Patients (pts) with Advanced Solid Tumors: Results from a Phase Ib/II Study
Presenter: Jean Fan, MD

2023 SABCS, December 5-9, San Antonio, TX, US.

Rapid-Fire Mini-Oral Presentation, Abstract #1572754
Title: The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC

"We are thrilled that tinengotinib clinical data has been selected for multiple oral and poster presentations in these impactful global scientific meetings. " Commented Dr. Frank Wu, chairman and CEO of TransThera, "It is a strong recognition from the community to tinengotinib as a very novel compound in global phase 3 development, capable of demonstrating efficacy in a variety of solid tumors with significant unmet medical needs. The upcoming presentations mark the potential of tinengotinib in CCA and breast cancer. We look forward to more discussions next year in other indications!"

About tinengotinib

Tinengotinib is a global innovative clinical-stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of Tinengotinib to be efficacious in various solid tumors. It was granted the Orphan-Drug Designation and Fast Track Designation by the FDA for the treatment of CCA. In July 2023, tinengotinib was granted the Breakthrough Therapy Designation (BTD) by NMPA in China.